REG - Oxford Biomedica PLC - Holdings in Company

Oxford BioMedicaAnnouncement

05/02/2021 13:25

RNS Number : 1974O
  
Oxford Biomedica PLC
  
05 February 2021
  
 

 
 
 
TR-1 annoucement of major holdings 
 
Oxford, UK - 5 February 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo/Lifesciences Fund, has advised the Group that on 4 February 2021 it sold 970,000 ordinary shares of 50p each in the Group. The shares have been acquired by a subsidiary of Vitruvian Investment Partnership III, a fund managed by Vitruvian Partners LLP. Vitruvian Partners is a leading global growth investment firm with €10bn AUM, and has supported some of Europe's most successful high growth innovators. They are highly respected with a long term focus and strong interest in cell and gene therapy.
 
Martin Diggle from VulpesTestudo/Lifesceinces Fund said: "Through the recent sale of a portion of our holding to Vitruvian Partners LLP, Oxford Biomedica gains another well respected long-term shareholder.  We are excited about the future for the Group, remain fully supportive of the business and continue to retain a significant shareholding."
 
 



NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i




 




1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: 


OXFORD BIOMEDICA PLC




1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)




Non-UK issuer








2. Reason for the notification (please mark the appropriate box or boxes with an "X")




An acquisition or disposal of voting rights


X




An acquisition or disposal of financial instruments


 




An event changing the breakdown of voting rights


 




Other (please specify)iii:


 




3. Details of person subject to the notification obligationiv




Name


VULPES LIFE SCIENCES FUND
VULPES TESTUDO FUND




City and country of registered office (if applicable)


CAYMAN ISLANDS




4. Full name of shareholder(s) (if different from 3.)v




Name


 




City and country of registered office (if applicable)


 




5. Date on which the threshold was crossed or reachedvi:


04/02/2021




6. Date on which issuer notified (DD/MM/YYYY):


05/02/2021




7. Total positions of person(s) subject to the notification obligation




 


% of voting rights attached to shares (total of 8. A)


% of voting rights through financial instruments

(total of 8.B 1 + 8.B 2)


Total of both in % (8.A + 8.B)


Total number of voting rights of issuervii




Resulting situation on the date on which threshold was crossed or reached


11.86%


0%


11.86%


9,768,615




Position of previous notification (if
applicable)


-


0%


 


 












 



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii




A: Voting rights attached to shares




Class/type of

shares
ISIN code (if possible)


Number of voting rightsix


% of voting rights




Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)


Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)


Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)




GB0006648157


9,768,615


 


11.86%


 




 


 


 


 


 




 


 


 


 


 




SUBTOTAL 8. A


9,768,615


11.86%




 
 




B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))




Type of financial instrument


Expiration

datex


Exercise/

Conversion Periodxi


Number of voting rights that may be acquired if the instrument is
exercised/converted.


% of voting rights




 


 


 


 


 




 


 


 


 


 




 


 


 


 


 




 


 


SUBTOTAL 8. B 1


 


 




 
 
 
 




B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))




Type of financial instrument


Expiration

datex


Exercise/

Conversion Period xi


Physical or cash
settlementxii


Number of voting rights


% of voting rights




 


 


 


 


 


 




 


 


 


 


 


 




 


 


 


 


 


 




 


 


 


SUBTOTAL 8.B.2


 


 




 
 
 















 



9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")




Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii


X




Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)


 




Namexv


% of voting rights if it equals or is higher than the notifiable threshold


% of voting rights through financial instruments if it equals or is higher than the notifiable threshold


Total of both if it equals or is higher than the notifiable threshold




 


 


 


 




 


 


 


 




 


 


 


 




 


 


 


 




 


 


 


 




 




10. In case of proxy voting, please identify:




Name of the proxy holder


 




The number and % of voting rights held


 




The date until which the voting rights will be held


 




 




11. Additional informationxvi




 










 



Place of completion


London, UK




Date of completion


04 February 2021



 



Contact name:


Natalie Walter




Contact telephone number:


01865 783000



 
 
-Ends-



 
 
Enquiries:








 
Oxford Biomedica plc 
 
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
 


 
 
 
T: +44 (0)1865 783 000
T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
 




 
Consilium Strategic Communications 
 
Mary-Jane Elliott/Matthew Neal 


 
 
 
T: +44 (0)20 3709 5700



 
 
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
HOLEADASEAEFEFA